Search for a command to run...
Promoter shareholding stable; institutions increased by 1.14% YoY, outperforming sector average which remained unchanged.
Public shareholding slightly decreased, indicating limited retail interest; however, strong institutional support suggests confidence in Ajanta Pharma's future.
In a sector with mixed performances, Ajanta's institutional growth stands out positively against peers like SANOFICONR (20.63% increase) and NECTAR LIFE (-15.93% decrease).
| Category | Trend | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
1Promoter Holdings | 66.21% | 66.21% | 66.27% | 66.26% | 66.26% | 66.26% | 66.26% | 66.25% | |
2Public Holdings | 8.01% | 7.76% | 7.95% | 7.52% | 7.45% | 7.39% | 7.37% | 7.31% | |
3Foreign Investors | 9.11% | 8.54% | 8.36% | 9.11% | 9.26% | 8.86% | 8.86% | 8.53% | |
4Domestic Investors | 16.67% | 17.49% | 17.42% | 17.11% | 17.03% | 17.49% | 17.51% | 17.91% |